MIMETAS
Founded Year
2013Stage
Grant | AliveTotal Raised
$28.9MValuation
$0000About MIMETAS
MIMETAS develops organ-on-a-chip technology for testing of new medicines. Its microfluidic technology enables testing of drug compounds in high-throughput on miniaturized organ models. These models have better predictivity compared to laboratory animals and conventional cell culture models. The MIMETAS OrganoPlate platform supports 3D cell culture under continuous perfusion, membrane-free co-culture and boundary- and gradient formation. MIMETAS develops and validates customised disease, toxicology and transport models and ultimately will make its technology available for personalized therapy selection.
Missing: MIMETAS's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
ESPs containing MIMETAS
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
These companies use patient-derived cells and tissue samples to create structures that mimic human physiology. These solutions come in two categories. Some vendors develop organoids, which are miniaturized and simplified versions of organs and tissue structures. Other vendors insert human cells into microfluidic assays in order to emulate human physiology.
MIMETAS named as Challenger among 11 other companies, including Emulate, Hubrecht Organoid Technology, and CN Bio Innovations.
Missing: MIMETAS's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing MIMETAS
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
MIMETAS is included in 4 Expert Collections, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
6,079 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Digital Health
12,671 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
MIMETAS Patents
MIMETAS has filed 8 patents.
The 3 most popular patent topics include:
- Biotechnology
- Microfluidics
- Cell biology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/15/2019 | 11/15/2022 | Grant |
Application Date | 5/15/2019 |
|---|---|
Grant Date | 11/15/2022 |
Title | |
Related Topics | |
Status | Grant |
Latest MIMETAS News
Mar 9, 2023
MIMETAS Launches Ready-to-Use 3D Adult Stem Cell Organoid Tubules Thursday, March 9, 2023 LEIDEN, the Netherlands, March 07 / B3C newswire / -- MIMETAS, a leading company in the field of organ-on-a-chip-based disease models, announces that it has launched its Adult Stem Cell (ASC)-derived tubular organoids in an assay-ready format. As part of its OrganoReady® product line, MIMETAS offers two organoid-based products: ASC-derived Colon1 and Kidney2 Organoid tubules. “We are thrilled to offer this cutting-edge technology to the research community,” says Jos Joore, co-CEO of MIMETAS. “We’ve worked for several years to optimize these OrganoReady® organoid products. As a result, our early-access users will be the first in the world to have license-free access to ready-to-use, donor-relevant organoid tubules of consistent quality.” MIMETAS has strategically collaborated with HUB Organoid Technology (HUB) since October 2019 to develop organoid models on a chip. HUB Organoids are derived directly from ASCs and do not require reprogramming or transforming stem cells, thus maintaining donor-specific properties. Combining the OrganoPlate®, MIMETAS’ proprietary microfluidic platform, with HUB organoid technology, organoids are grown as perfused 3D tubular structures that can be accessed on both apical and basal sides. The fully optimized OrganoReady® Colon Organoid and OrganoReady® Kidney Organoid products are ideal for applications such as mechanistic toxicology and drug-induced organ injury. With 64 organoids on a single plate, the models are amenable to medium- to high-throughput screening. In addition MIMETAS can develop any type of organoid model in the OrganoPlate® on request. The launch comes at a strategic moment. Recently, the FDA Modernization Act 2.0 was signed by US president Joe Biden. The act advocates the use of innovative technologies such as organoids and Organ-on-a-Chip as alternatives to animal testing. For high resolution please click the image. About MIMETAS MIMETAS (Leiden, The Netherlands) is a global leader in disease modeling using organ-on-a-chip technologies. Its proprietary OrganoPlate® platform enables the development and high-throughput screening of physiologically relevant disease models for drug discovery and development. The company offers its technology and expertise in therapy co-development projects, services, and off-the-shelf products. MIMETAS works with leading pharmaceutical and biotech companies worldwide to develop novel therapies against unsolved diseases. Founded in 2013 in Leiden, the Netherlands, MIMETAS has grown into a multinational company with operations in Europe, Asia, and the USA. To learn more about MIMETAS' disease modeling capabilities and its OrganoPlate® platform, visit www.mimetas.com. Contact MIMETAS BV Jos Joore, CEO This email address is being protected from spambots. You need JavaScript enabled to view it. References 1. Gijzen et al., 2021 Nature Protocols 2. Schutgens et al., 2019 Nature Biotechnology Keywords: Animals; Models, Biological; Biological Assay; High-Throughput Screening Assays; Research; Laboratories; Lab-On-A-Chip Devices; Drug Discovery; Drug Development; Organoids; Adult Stem Cells; Kidney; Technology; Biotechnology; Netherlands
MIMETAS Frequently Asked Questions (FAQ)
When was MIMETAS founded?
MIMETAS was founded in 2013.
Where is MIMETAS's headquarters?
MIMETAS's headquarters is located at J.H. Oortweg 19, Leiden.
What is MIMETAS's latest funding round?
MIMETAS's latest funding round is Grant.
How much did MIMETAS raise?
MIMETAS raised a total of $28.9M.
Who are the investors of MIMETAS?
Investors of MIMETAS include Horizon 2020, Aglaia Oncology Funds, InnovationQuarter, European Life Sciences Growth Fund, Korys and 7 more.
Who are MIMETAS's competitors?
Competitors of MIMETAS include Xellar Biosystems and 3 more.
Compare MIMETAS to Competitors
Emulate focuses on commercializing Organs-on-Chips as an automated, human bio-emulation platform that achieves a new standard for mimicking human physiology so that responses to medicines, chemicals, and diseases can be accurately predicted.
TissUse is a growth company that has developed a Multi-Organ-Chip platform that provides preclinical insight on the systemic level using human tissue. This enabling technology platform consists of a miniaturized construct that simulates the activity of multiple human organs in their true physiological context. TissUse's Multi-Organ-Chips provide an approach to predict, for example, toxicity, ADME profiles, and efficacy in vitro, reducing and replacing laboratory animal testing and streamlining human clinical trials.
CN Bio provides micro-physiological systems that enable researchers to study drug metabolism, toxicology and specific disease models on single- and multi-organ systems. Providing efficiencies for pre-clinical drug testing with predictive human tissue-based data, the company’s technologies are able to replicate the micro-environments, cell-cell interactions and biological processes that occur in vivo, to bridge the gap between traditional cell culture assays and human studies, improving drug discovery while reducing research and development costs.
React4life is a biotech company that offers fluid devices for in vitro testing. The approach is based on a technology that recreates physiological environments and allow the cultivation of 3D tissues, more similar to human ones, of clinically relevant dimensions on which to perform in vitro testing. The project aims to improve the effectiveness of laboratory tests, experiment with therapeutic approaches, and reduce animal testing.
Stemnovate delivers drug-screening and safety-testing platforms. Its user-friendly, flexible platforms overcome the limitations of mammalian cell-lines and in-vivo models commonly used in drug-discovery.
InSphero provides pharmaceutical and biotechnology services. It focuses on industrial-grade, 3D-cell-based assay solutions, and 3D organ-on-a-chip technology. The company specializes in liver toxicology, metabolic diseases (diabetes and NASH liver disease), and Immuno oncology. InSphero was founded in 2009 and is based in Schlieren, Switzerland.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.